WINT Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc., a biotechnology and medical device company, focuses on developing drug product candidates and medical device technologies to address acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime for the treatment of acute decompensated heart failure; AEROSURF for treating non-invasive delivery of its lyophilized KL4 surfactant to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant intratracheal suspension for RDS; and rostafuroxin for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

$1.71
As of 11/30/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/08/1995
Outstanding shares:  28,268,926
Average volume:  241,869
Market cap:   $49,753,310
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    97382D303
ISIN:        US97382D3035
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.93
PS ratio:   0.00
Return on equity:   -123.59%
Net income %:   0.00%